.jpg)
A New Patient-Centered World is Emerging in Hematology
According to a recent article in the ASH Clinical News patients are being encouraged to participate in shared decision-making (SDM) with their doctors, nurses and other medical personnel. The…
source: pixabay.com
First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
According to a story from Myeloma Research News, the first patient has been dosed with an experimental allogeneic (donor derived) CAR-T cell therapy called UCARTCS1 as part of a phase…
<a href="https://pixabay.com/users/pasja1000/">pasja1000</a> / Pixabay
Study Finds Under-Use of Supportive Care in Older Multiple Myeloma Patients
According to a story from Healio, a recent study has determined that older patients with multiple myeloma, a rare cancer that affects plasma cells, routinely under-utilize supportive care resources as…
<a href="https://pixabay.com/users/12019/">12019</a> / Pixabay
Takeaways From The Myeloma Charlotte Plasma Cell Disorder Conference
According to a story from Myeloma Crowd Crowdcare Foundation, the very first Plasma Cell Disorder Congress recently took place in Charlotte, NC from August 10-11, 2019. The event primary focused…
.png)
British Science Journal Authors Voice Concerns Over Low Standards Supporting Cancer Drugs
Fierce Biotech recently focused on a report by The BMJ, a British science journal, on the validity of clinical trials which are critical to decision making by patients and…
<a href="https://pixabay.com/users/mwooten/">mwooten</a> / Pixabay
Dual CAR-T Cell Therapy Shows Potential for Treating Multiple Myeloma
According to a story from Medpage Today, a recent phase II clinical trial of an experimental dual-action CAR-T cell therapy has yielded an impressive 95 percent response rate. The drug…
Immunizations and Rare Diseases: A Resource
The Immunization Action Coalition (IAC) Express Newsletter reports that 981 cases of measles have been reported so far this year, with 41 new cases added just last week. Rare disease kids…
Multiple Myeloma Drug ‘Xpovio’ Passes With FDA Accelerated Approval
As reported in Biospace, xpovio (selinexor), a drug used to treat relapsed refractory multiple myeloma, received accelerated approval by the Food and Drug Administration this July. About Multiple Myeloma Multiple…
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay
New Treatment for Multiple Myeloma Gains FDA Approval
According to a story from PR Newswire, the drug selinexor (marketed as Xpovio), which was developed by Karyopharm Therapeutics, was recently approved by the US Food and Drug Administration (FDA)…
.jpg)
A Look at Progress in Healthcare and a Glimpse into the Future
The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay
Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation
According to a story from globenewswire.com, the biopharmaceutical company Poseida Therapeutics, Inc. recently announced that the company's investigational product candidate P-BCMA-101 has been granted Orphan Drug Designation from the US…
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay
Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation
According to a story from globenewswire.com, the biopharmaceutical company Poseida Therapeutics, Inc. recently announced that the company's investigational product candidate P-BCMA-101 has been granted Orphan Drug Designation from the US…
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay
Early Trial Data for Experimental Multiple Myeloma Drug Shows Promise
According to a story from EurekAlert!, the biopharmaceutical company Celgene Corporation and the gene therapy company bluebird bio, inc. recently announced that the interim results for a Phase 1 clinical…
<a href="https://pixabay.com/users/skeeze/">skeeze</a> / Pixabay
New Combination Therapy for Multiple Myeloma Approved in England
According to a story from Myeloma Research News, the UK National Institute of Health and Care Excellence (NICE) has recently decided to approve a three part combination treatment for coverage…
Preliminary Data from Phase 1 Trial for Multiple Myeloma Indicates Complete Response in a Patient
Phase 1 Trial A Phase 1 trial by Gamida Cell is examining a new potential treatment option for patients with multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma who have not responded…
<a href="https://pixabay.com/users/klbz/">klbz</a> / Pixabay
Treatment Strategies for Younger Multiple Myeloma Patients
According to a story from ASH Clinical News, the treatment of younger patients with multiple myeloma, a form of rare blood cancer, requires physicians to take into account certain factors…
New Phase I/II Trial for Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Multiple Myeloma is Now Underway!
The very first patient in Medigene AG's clinical trial examining MDG1011 has officially received the treatment. This is the company's first human clinical trial for this TCR therapy. The trial…
Patient Advocate Foundation Provides Co-Pay Relief for Rare Disease Patients
What is the Patient Advocate Foundation? The Patient Advocate Foundation (PAF) is a non-profit, formed in 1994 that has one primary aim- eliminate the barriers to treatment too many patients…
Positive Results from Phase 3 Trial for Multiple Myeloma!
Multiple Myeloma Multiple Myeloma is a rare form of cancer that develops in the body's plasma cells. These cells are normally responsible for helping the body fight infection. The accumulation…
1 Million to Fund Software Which Could Improve Treatment Plans for Multiple Myeloma Patients
We've made a lot of progress in cancer research in recent years. Many novel therapies have been developed for illnesses previously considered untreatable. However, as new treatments have been discovered,…
Effect of Government Shutdown on Rare Disease Research
The government shutdown hasn't had any startling affects on rare disease research yet, but drug developers have voiced their concern that it could soon begin to hinder the research process.…
Source: Pixabay.com
Disparities in Cancer Care Addressed by the NCCN
"People always say that 'cancer doesn't discriminate,' but the healthcare system often does," -Liz Margolies, LCSW, Executive Director, National LGBT Cancer Network. Unfortunately, the reality of this statement is that there…
Source: Pixabay.com
Research Updates for Multiple Myeloma and WM!
Dana-Farber Cancer Institute has just announced research updates on multiple myeloma and waldenstrom macroglobulinemia which indicate significant progress in the search for treatments for these diseases. The Findings 1) There…
<a href="https://pixabay.com/users/crystal710/">crystal710</a> / Pixabay
Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
According to a story from PR Newswire, the 60th Annual Meeting of the American Society of Hematology has been generating a lot of press lately as many groundbreaking studies, research,…
<a href="https://pixabay.com/users/mwooten/">mwooten</a> / Pixabay
Enrollment is Complete for Trial of Experimental Multiple Myeloma Treatment
According to a story from BioPortfolio, Celgene Corporation and bluebird bio, Inc., have recently announced that enrollment for a pivotal Phase 2 study testing an experimental therapy for relapsed/refractory multiple…
